![]() Net Loss: Net loss was $53.0 million and $198.3 million for the three and twelve months ended December 31, 2022, compared to $93.3 million and $348.1 million for the three and twelve months ended December 31, 2021.The decrease was primarily attributable to reduced other selling, general and administrative costs as a result of our withdrawal of UKONIQ and decreased headcount during the period ended December 31, 2022, as well as decreased non-cash compensation G&A expense during the twelve months ended Decemover the comparable period in 2021. SG&A Expenses: Total selling, general and administrative (SG&A) expense was $22.5 million and $70.0 million for the three and twelve months ended December 31, 2022, and $32.4 million and $128.1 million for the three and twelve months ended December 31, 2021.The decrease in R&D expense is primarily attributable to reduced clinical trial related expenses, license milestones and manufacturing expense, decreased headcount and lower fees paid to consultants and outside service providers, as well as a decrease in non-cash compensation R&D expense during the twelve months ended Decemover the comparable period in 2021. R&D Expenses: Total research and development (R&D) expense was $29.6 million and $125.4 million for the three and twelve months ended December 31, 2022, compared to $62.6 million and $222.6 million for the three and twelve months ended December 31, 2021.sales of UKONIQ, which received approval in February of 2021 and was withdrawn from the U.S. Net product revenues during the year represent U.S. Product Revenue, net: Product revenue, net was approximately zero and $2.6 million for the three and twelve months ended December 31, 2022.Continue to present additional data from the ULTIMATE I & II Phase 3 trials of BRIUMVI in RMSįinancial Results for the Fourth Quarter and Full Year 202 2.Obtain broad payor coverage for BRIUMVI.Execute a strong commercial launch of BRIUMVI in RMS.Presented additional data, including new analyses, from the ULTIMATE I and II Phase 3 trials at the 2022 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and at the 2023 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum. ![]() Commercially launched BRIUMVI making it available for patients and physicians.Food and Drug Administration (FDA) approved BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. We look forward to building on the foundation we are developing in this early launch phase and extending it throughout 2023 and beyond.” Weiss continued, “Our highest priority is our commitment to patients and to ensure that patients who want BRIUMVI will have access to BRIUMVI. ![]() ![]() Our teams are hard at work introducing BRIUMVI to the MS community and while we are only 4 weeks into the launch, we are encouraged by the early feedback from providers, payors and advocates.” Mr. Weiss, the Company's Chairman and Chief Executive Officer, stated, "2022 was a pivotal year for TG with the approval of BRIUMVI for relapsing forms of Multiple Sclerosis, and 2023 is off to an exciting start with the commercial launch of BRIUMVI. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2022, and recent company developments. 28, 2023 (GLOBE NEWSWIRE) - TG Therapeutics, Inc. Earnings Release TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |